Biotest Ag

Diaclone

Sumitomo Pharmaceuticals Company Limited

Université De Franche Comte

Centre Regional De Transfusion Sanguine

Mab Designs Limited

Efs Bourgogne Franche Comte

Diaclone S.a. a Directoire Et Conseil De Surveillance

Biotest Pharma Gbmh

Etablissement Francais Du Sang

Ogen Gmbh

John Wijdenes

Helmut Jonuleit

Claude Clement

Hiroshi Noguchi

Hideyuki Gomi

Christophe Borg

Camille Grandclement

Brigitte Morel-Fourrier

Patrick Herve

Tomoyuki Nakatani

Andre Peters

Camille Grand Clement

The present invention discloses a reliable and efficient method of generating an antibody which can discriminate between the membrane bound form of an antigen and the soluble form of the same antigen. Said method comprises the steps of: (i) immunizing an animal with a first antigen which comprises either the membrane bound form or the soluble form of the antigen; (ii) administering to the animal an agent which selectively kills rapidly dividing cells; (iii) when the first antigen of step (i) comprises the soluble form, immunizing the animal with a second antigen which comprises the membrane bound form of the antigen, or when the first antigen of step (i) comprises the membrane bound form, immunizing the animal with a second antigen which comprises the soluble form of the antigen; and (iv) screening for an antibody which can bind to the second antigen but which does not bind to the first antigen.

Method of generating antibodies

A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.

Humanized anti-CD4 antibody with immunosuppressive properties

The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumor cell apoptosis in the context of an anticancer treatment.

Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers

Method for screening for an anti-CD4 antibody suitable for use in immunotherapy

Humanized B-B10

The invention relates to anti-gp130 monoclonal antibodies, as well as to their uses for obtaining medicinal products, cell culture adjuvants and diagnostic reagents.

Anti-gp130 monoclonal antibodies

New monoclonal murine-IgG.sub.1 antibody obtainable from a new hybridoma-cell line, binding to an epitope of the human interleukin-2 receptor that differs from Tac, inhibiting the binding of human interleukin-2 to its receptor, and appropriate for the treatment, prophylaxis, and diagnosis of interleukin-2-dependent diseases in humans.

Monoclonal antibody to the interleukin-2-receptor and its use

Growing community of inventors

Larnod, France

John Wijdenes